Over the past several decades, messenger RNA (mRNA) vaccines have progressed from a
scepticism-inducing idea to clinical reality. In 2020, the COVID-19 pandemic catalysed the …

The development of effective vaccines to combat infectious diseases is a complex multi-year
and multi-stakeholder process. To accelerate the development of vaccines for coronavirus …

Background Respiratory syncytial virus (RSV) can cause substantial morbidity and mortality
among older adults. An mRNA-based RSV vaccine, mRNA-1345, encoding the stabilized …

Nirsevimab is an extended half-life monoclonal antibody specific for the prefusion
conformation of the respiratory syncytial virus (RSV) F protein, which has been studied in …

A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to
control the coronavirus disease 2019 (COVID-19) global pandemic. Structural studies have …

Background Respiratory syncytial virus (RSV), a major cause of illness and death in infants
worldwide, could be prevented by vaccination during pregnancy. The efficacy …

Respiratory syncytial virus (RSV) is responsible for a significant proportion of global
morbidity and mortality affecting young children and older adults. In the aftermath of formalin …

Coronaviruses (CoVs) have caused outbreaks of deadly pneumonia in humans since the
beginning of the 21st century. The severe acute respiratory syndrome coronavirus (SARS …

Since the emergence of COVID-19, caused by the SARS-CoV-2 virus at the end of 2019,
there has been an explosion of vaccine development. By 24 September 2020, a staggering …

Respiratory syncytial virus (RSV) is the leading, global cause of serious respiratory disease
in infants and is an important cause of respiratory illness in older adults. No RSV vaccine is …